Buffalo, NYNCT06222593Now EnrollingIRB Ready

Carcinoma, Renal Cell Clinical Trial in Buffalo, NY

Access cutting-edge carcinoma, renal cell treatment through this clinical trial at a research site in Buffalo. Study-provided care at no cost to qualified participants.

Sponsored by State University of New York at Buffalo

Quick Self-Assessment

See if you qualify for this Buffalo location

Preparing your pre-screening questions…

Expert Care in Buffalo

Access carcinoma, renal cell specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related carcinoma, renal cell treatment provided free

Apply for This Buffalo Location

Check if you qualify for this carcinoma, renal cell clinical trial in Buffalo, NY

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Buffalo

    Convenient for NY residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Buffalo site if eligible
  4. 4Begin participation

About This Carcinoma, Renal Cell Study in Buffalo

This is a Phase I/II open-label, efficacy and safety study of bicalutamide in combination with sunitinib in patients with advanced renal cell carcinoma (RCC) who have been treated with a receptor tyrosine kinase inhibitor (RTKI) and experienced disease progression.

Sponsor: State University of New York at Buffalo

Who Can Participate

Inclusion Criteria

Be willing and able to provide written informed consent for the trial.
Be greater than or equal to 18 years of age on day of signing informed consent.
Have measurable disease based on RECIST 1.1
Have a performance status of 0-2 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale
Demonstrate adequate organ function
Female subject of childbearing potential should have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study medication.
Subjects of childbearing potential should be willing to use 2 methods of contraception for the course of the study through 120 days after the last dose of study medication
Male subjects without a previous vasectomy should agree to use an adequate method of contraception (i.e. abstinence, condom with spermicidal foam/gel/film/cream) starting with the first dose of study therapy through 120 days after the last dose of study therapy.
Subjects have archival tumor tissue available or are willing to undergo a baseline biopsy prior to treatment.
Subjects must have a life expectancy of at least 6 months.

Exclusion Criteria

Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment.
Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment.
Has active Bacillus tuberculosis (TB)
Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer.
Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
Has an active infection requiring systemic therapy.
Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.
Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment.
Has a known history of Human Immunodeficiency Virus (HIV)
Has known active Hepatitis B or Hepatitis C
Has received a live vaccine within 30 days of planned start of study therapy

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Buffalo?

Yes, this clinical trial (NCT06222593) has an active research site in Buffalo, NY that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Carcinoma, Renal Cell Treatment Options in Buffalo, NY

If you're searching for carcinoma, renal cell treatment options in Buffalo, NY, this clinical trial (NCT06222593) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Buffalo research site is actively enrolling participants for this clinical trial. You'll receive care from experienced carcinoma, renal cell specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Ready to Join in Buffalo?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Buffalo, NY